Indian drug makers shifting R&D operations to South East Asia: Survey
Tuesday, July 9, 2013
AHMEDABAD: Red tapism is pushing India’s Rs 1,00,000 crore pharmaceutical industry in peril as most of the pharma companies shifting research and development (R&D) operations and clinical trials to South-East Asian countries of Cambodia, Korea, Philippines, Singapore, Thailand, Vietnam and others, according to a just concluded survey by ASSOCHAM.
“Various South-East Asian countries are wooing India’s R&D industry by offering sops and transparent regulations as regulatory bottlenecks and a plethora of committees have slowed permissions/approvals for trials or marketing drugs to more than 12-15 months back home in India while such permissions are given by the USFDA, EU and Singapore within a month’s time,” according to a survey of Indian Pharma Industry conducted by industry body The Associated Chambers of Commerce and Industry of India (ASSOCHAM).
ASSOCHAM interacted with about 250 top officials and representatives from India’s pharma industry based out of five states of Andhra Pradesh, Gujarat, Karnataka, Maharashtra and Tamil Nadu between March-June, 2013 to ascertain and seek solution to their concerns and problems.
Subscribe to NextBillion Notes in September for a FREE GIVEAWAY
Get NextBillion's top articles, jobs, events – and a FREE chapter of 'Social Value Investing: A Management Framework for Effective Partnerships,' by Howard W. Buffett and William B. Eimicke – delivered to your inbox each Wednesday this month.
We respect your privacy. Your information is safe and will never be shared.